|
|
Article: Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer.(Clinical report)
- Article from:
- Business Wire
- Article date:
- June 2, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- Results Add to Avastin Data in Most Common Form of Advanced Lung Cancer --
CHICAGO -- Genentech, Inc. (NYSE:DNA) today announced that a Roche-sponsored, randomized placebo controlled Phase III clinical study (AVAiL) demonstrated that Avastin([R]) (bevacizumab), studied at two different doses in combination with gemcitabine and cisplatin chemotherapy, significantly increased the time patients with advanced non-small cell lung cancer (NSCLC) lived without their disease advancing, as defined by progression-free survival (PFS). The investigator-assessed analysis showed similar improvements in PFS among patients in the two Avastin plus gemcitabine and cisplatin ...